Sarepta Therapeutics, Inc.
US ˙ NasdaqGS ˙ US8036071004

SecuritySRPT / Sarepta Therapeutics, Inc.
InstitutionBlackRock Variable Series Funds, Inc. - BlackRock Managed Volatility V.I. Fund Class I
Latest Disclosed Ownership134 shares
Latest Disclosed Value $ 2,291
BlackRock Variable Series Funds, Inc. - BlackRock Managed Volatility V.I. Fund Class I reports 79.97% decrease in ownership of SRPT / Sarepta Therapeutics, Inc.

On August 28, 2025 - BlackRock Variable Series Funds, Inc. - BlackRock Managed Volatility V.I. Fund Class I filed a NPORT-P form disclosing ownership of 134 shares of Sarepta Therapeutics, Inc. (US:SRPT) valued at $2,291 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 27, 2025 disclosing 669 shares of Sarepta Therapeutics, Inc.. This represents a change in shares of -79.97% during the quarter. The current value of the position is $2,720 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-28 2025-06-30 NP Sarepta Therapeutics EC US8036071004 134 -535 -79.97 2 -95.24 0.0015
2025-05-27 2025-03-31 NP Sarepta Therapeutics EC US8036071004 669 359 115.81 43 13.51 0.0285
2025-02-27 2024-12-31 NP Sarepta Therapeutics EC US8036071004 310 0 0.00 38 -2.63 0.0233
2024-11-26 2024-09-30 NP Sarepta Therapeutics EC US8036071004 310 9 2.99 39 -19.15 0.0238
2024-08-27 2024-06-30 NP Sarepta Therapeutics EC US8036071004 301 -223 -42.56 48 -29.85 0.0288
2024-05-28 2024-03-31 NP Sarepta Therapeutics EC US8036071004 524 374 249.33 68 378.57 0.0396
2024-02-27 2023-12-31 NP Sarepta Therapeutics EC US8036071004 150 24 19.05 14 -33.33 0.0087
2021-02-24 2020-12-31 NP Sarepta Therapeutics EC US8036071004 126 -70 -35.71 21 -32.26 0.0096
2020-08-24 2020-06-30 NP Sarepta Therapeutics EC US8036071004 196 -275 -58.39 31 -32.61 0.0151
2020-05-26 2020-03-31 NP Sarepta Therapeutics EC US8036071004 471 196 71.27 46 31.43 0.0227
2020-02-25 2019-12-31 NP Sarepta Therapeutics EC 803607100 275 -225 -45.00 35 -5.41 0.0150
2019-11-25 2019-09-30 NP Sarepta Therapeutics EC US8036071004 500 500 38 0.0160
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.